AbbVie (ABBV) Research & Development (2012 - 2026)
AbbVie's Research & Development was $2.34 billion in Q2 2026, up 10.0% from $2.13 billion a year earlier but down 5.2% from the prior quarter.
Powered by 
Analysis
AbbVie (ABBV) Research & Development (2012 - 2026) Analysis & Trends
On a trailing twelve-month basis, AbbVie's Research & Development was $9.71 billion through Jun 30, 2026, down 25.9% year-over-year; for FY2025, it was $9.1 billion, down 28.9% from FY2024.
- Research & Development shows a five-year compound annual growth rate of 7.4% (FY2020 to FY2025).
- In earlier years, Research & Development was $12.79 billion in FY2024 (+66.7%), $7.68 billion in FY2023 (+17.9%), $6.51 billion in FY2022 (-6.0%) and $6.92 billion in FY2021 (+8.5%).
- Quarterly Research & Development has moved between $1.5 billion (Q1 2022) and $6.77 billion (Q4 2024) over five years.
- Compared with a year earlier, Research & Development was higher in seven of the last eight quarters, with growth averaging 33.5%.
- The best year-over-year quarter for Research & Development over five years was Q4 2024 (growth of 251.5%); the worst was Q4 2025 (a decline of 61.9%).
- Per Business Quant data, ABBV's Research & Development in the three quarters before Q2 2026 was $2.47 billion (Q1 2026), $2.58 billion (Q4 2025) and $2.32 billion (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.01 Bn | 563.54 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 465.23 Bn | 438.39 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 368.40 Bn | 322.83 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 278.02 Bn | 233.89 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 254.57 Bn | 228.13 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 229.02 Bn | 184.42 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 187.74 Bn | 161.85 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.45 Bn | 105.45 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Bristol Myers Squibb | 128.45 Bn | 79.72 Bn | 9.25 Bn | 2.96 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.34 Bn |
| Mar 31, 2026 | 2.47 Bn |
| Dec 31, 2025 | 2.58 Bn |
| Sep 30, 2025 | 2.32 Bn |
| Jun 30, 2025 | 2.13 Bn |
| Mar 31, 2025 | 2.07 Bn |
| Dec 31, 2024 | 6.77 Bn |
| Sep 30, 2024 | 2.13 Bn |
| Jun 30, 2024 | 1.95 Bn |
| Mar 31, 2024 | 1.94 Bn |
| Dec 31, 2023 | 1.93 Bn |
| Sep 30, 2023 | 1.72 Bn |
| Jun 30, 2023 | 1.73 Bn |
| Mar 31, 2023 | 2.29 Bn |
| Dec 31, 2022 | 1.79 Bn |
| Sep 30, 2022 | 1.61 Bn |
| Jun 30, 2022 | 1.61 Bn |
| Mar 31, 2022 | 1.50 Bn |
| Dec 31, 2021 | 1.83 Bn |
| Sep 30, 2021 | 1.66 Bn |
API Access
AbbVie Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=ABBV&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "ABBV", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=ABBV&period=max&api_key=YOUR_API_KEY");
const data = await res.json();